
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics is a pre-commercial stage company with a promising pipeline of targeted therapeutics for neuromuscular diseases, utilizing their innovative FORCE platform. However, the company faces significant competition and will likely need to raise debt or equity funds in the future. The success of their clinical trials, potential regulatory challenges, and ultimate market penetration will determine the company's future financial performance. Despite these risks, the potential for a positive read-through from competitor Avidity's DM1 Phase III readout in 2026 could lead to significant upside potential for Dyne's stock.
Bears say
Dyne Therapeutics is a pre-commercial stage company that faces significant competition in the gene therapy/oligonucleotide medicines space. Its key intellectual property could fail to protect its products and it may face legal expenses from potential IP infringement suits. The company's development pipeline has products that could be protected by market exclusivity from orphan drug designations, but there is no assurance that this will ultimately provide protection against competitors. Dyne also faces additional clinical and regulatory risks, and its future fundraising and stock prices may be impacted by the progress of its research and clinical programs.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares